Guides May 20, 2026

Eloralintide: Lilly's Amylin Drug Has the Strongest Standalone Phase 2 Weight-Loss Result So Far

Eloralintide is Eli Lilly's once-weekly selective amylin receptor agonist for obesity. Its Phase 2 Lancet data showed up to 20.1% mean weight loss at 48 weeks, putting it at the front of the standalone amylin race.

Eloralintide is the piece that makes the current amylin race make sense.

If you only looked at recent obesity-pipeline headlines, you could easily come away with the impression that the amylin story was mostly:

Novo Nordisk with cagrilintide and CagriSema
Roche + Zealand with petrelintide
and a lot of speculation about what comes after GLP-1

But Lilly is not just participating in that race.

Based on the current published monotherapy data, Lilly may have the strongest standalone amylin result in the field.

That does not mean eloralintide has already won anything clinically.

Cross-trial comparisons are messy, and Phase 3 is where these stories get sorted out.

But as of May 20, 2026, the cleanest fair summary is:

eloralintide has the strongest published Phase 2 weight-loss signal of any standalone amylin monotherapy in obesity so far.

What eloralintide is

Eloralintide, previously known as LY3841136, is Eli Lilly’s investigational once-weekly selective amylin receptor agonist for weight management.¹²

That wording matters.

Lilly consistently describes eloralintide as a selective amylin receptor agonist, not just another broad obesity poly-agonist.¹³

It is being developed as:

a standalone weekly therapy
and as a potential combination partner with incretin-based treatment¹³

That makes it a direct strategic answer to:

Novo’s cagrilintide / CagriSema path
Roche and Zealand’s petrelintide path
and the broader industry move toward multi-mechanism obesity treatment

Why the amylin pathway still matters

Amylin is a peptide hormone co-secreted with insulin by pancreatic beta cells.

Reviews of amylin-based obesity pharmacology describe its physiological roles as including:

promoting satiety
slowing gastric emptying
and suppressing postprandial glucagon⁴

That is why amylin keeps coming back as a serious obesity target even in the GLP-1 era.

It gives companies a mechanistically distinct appetite-regulation pathway that can be used:

on its own
alongside incretins
or eventually in fixed-dose or unimolecular combinations

The Phase 2 result is why the competitive picture changed

The key dataset is the 48-week phase 2 trial published in The Lancet on November 6, 2025 and presented at ObesityWeek 2025.²¹

This was a multicentre, double-blind, randomized, placebo-controlled trial in 263 adults with:

obesity
or overweight plus at least one weight-related comorbidity
and without type 2 diabetes²

Participants were randomized to once-weekly subcutaneous placebo or multiple eloralintide regimens for 48 weeks.²

According to the published trial and Lilly’s release, the mean percent change in bodyweight at week 48 was:

-9.5% with 1 mg
-12.4% with 3 mg
-17.6% with 6 mg
-20.1% with 9 mg
-19.9% with 6-to-9 mg escalation
-16.4% with 3-to-6-to-9 mg escalation
versus -0.4% with placebo¹²

The headline number is the one everyone noticed:

20.1% mean weight loss at 48 weeks with the 9 mg dose
corresponding to about 21.3 kg, or roughly 47 pounds¹

That is a very large monotherapy signal.

Why that number matters in the amylin race

The easiest way to overread eloralintide is to pretend all obesity trials are directly comparable.

They are not.

Different trials use:

different populations
different durations
different dose-escalation schemes
different estimands
and different background interventions

So the comparison needs humility.

Still, there is a reason eloralintide changed the conversation.

Using the widely cited standalone obesity monotherapy results:

cagrilintide reached about 10.8% at 26 weeks in its phase 2 dose-finding program⁵
petrelintide reached up to 10.7% at 42 weeks in ZUPREME-1⁶
eloralintide reached 20.1% at 48 weeks in its published phase 2 trial¹²

That does not prove eloralintide is categorically “better” than every other amylin program.

Petrelintide, for example, has been positioned heavily around tolerability and future combination use, not just maximum monotherapy efficacy.

But it does justify a narrower and more defensible claim:

Among the current published standalone amylin obesity datasets, eloralintide has the strongest headline weight-loss result.

Tolerability is why the result is more than just a flashy number

If eloralintide had delivered a big efficacy number with unacceptable tolerability, the story would be much weaker.

That is not how Lilly framed the result, and it is not how the published paper reads.

In the PubMed abstract, the most common adverse events were:

nausea
and fatigue²

Lilly’s release says the most common adverse events were mild-to-moderate gastrointestinal symptoms and fatigue, seen more frequently in the higher-dose groups, while the incidence of those events in the 1 mg and 3 mg groups was similar to placebo.¹

The Lancet abstract concludes that eloralintide was generally well tolerated and produced clinically meaningful, dose-dependent reductions in bodyweight over 48 weeks.²

That combination is what makes the program notable:

strong efficacy signal
weekly administration
and no obvious collapse in tolerability credibility at the publication stage

That still does not mean tolerability is “solved.”

Phase 3 is where discontinuation behavior, real adherence patterns, and scaling issues get much clearer.

But the phase 2 package is strong enough that Lilly was able to move quickly.

Lilly moved into Phase 3 fast

On the same day Lilly announced the phase 2 results, the company said it planned to begin Phase 3 enrollment by year-end 2025.¹

By 2026, that had already translated into multiple active ENLIGHTEN studies on ClinicalTrials.gov, including:

ENLIGHTEN-1 in adults with obesity or overweight without type 2 diabetes⁷
ENLIGHTEN-2 in adults with obesity or overweight and type 2 diabetes⁸
ENLIGHTEN-6 in adults with persistent obesity or overweight already treated with a weekly incretin, with and without type 2 diabetes⁹

That matters because Lilly is not treating eloralintide as a one-shot monotherapy experiment.

It is mapping the asset across:

obesity without diabetes
obesity with diabetes
and add-on use on top of existing weekly incretin therapy

That is late-stage platform behavior, not exploratory tinkering.

The tirzepatide combination strategy may be the most important commercial angle

Eloralintide is not only a monotherapy program.

Lilly has also been studying eloralintide alone and in combination with tirzepatide in adults with overweight or obesity.¹³¹⁰

That combination angle matters more than it may look at first glance.

Why?

Because Lilly already owns the biggest incretin obesity brand in the market:

tirzepatide as Zepbound for obesity
and Mounjaro for type 2 diabetes

So compared with competitors, Lilly has a different kind of strategic advantage:

Novo’s combination story involves CagriSema
Roche and Zealand are building toward petrelintide + CT-388 / enicepatide
Lilly can potentially pair investigational eloralintide with an incretin molecule that is already well established commercially

That does not make approval automatic.

But it does make the business logic unusually strong.

Why this is the cleanest way to think about the three-player amylin race

Right now the three biggest amylin stories look very different:

Novo Nordisk

cagrilintide as the standalone amylin analog
CagriSema as the amylin + GLP-1 combination
amycretin as the unimolecular GLP-1 + amylin design

Roche + Zealand

petrelintide as a more tolerability-focused amylin program
with combination plans alongside CT-388 / enicepatide

Eli Lilly

eloralintide as the strongest published standalone amylin monotherapy dataset so far
with a clear strategy to combine it with tirzepatide

That means Lilly’s position is not just “third entrant.”

It is probably better described as:

the player with the best current standalone amylin efficacy readout and one of the clearest combination paths.

The real takeaway

Eloralintide matters because it changed what “good amylin data” looks like.

Before its phase 2 readout, the amylin conversation was easier to frame around:

tolerability
complementarity with GLP-1 biology
and combination potential

After the Lancet paper and Lilly’s November 6, 2025 announcement, the conversation also had to include this:

an amylin monotherapy can potentially produce around 20% mean weight loss
with a published 48-week dataset
and move directly into a serious Phase 3 program

That does not settle the race.

What still needs to happen is obvious:

Phase 3 has to confirm the effect
tolerability has to hold up at larger scale
and the tirzepatide-combination strategy has to prove it adds something clinically meaningful

But as of May 20, 2026, the strongest concise summary is:

eloralintide looks like Lilly’s best amylin obesity asset, the strongest published standalone amylin monotherapy so far, and one of the most important non-GLP-1 names in the obesity pipeline.